The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help doctors assess a ...
5don MSN
US FDA approves first AI tool for liver disease trials: How AIM-NASH transforms biopsy reading
NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative technology assists pathologi ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their ...
At the Liver Meeting sponsored by the American Association for the Study of Liver Diseases, investigators presented new ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early ...
Metabolic dysfunction-associated steatotic liver disease (MASLD), a spectrum of liver conditions ranging from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, represents a global ...
Mirum Pharmaceuticals acquires Bluejay Therapeutics to expand its pipeline into liver diseases. Read more here.
Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...
Study shows that targeting S100A11 reduces steatohepatitis and identifies HK2 as a critical mediator of lipotoxicity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback